Sustained Improvement Observed in ATA188 Treated Patients Achieving Confirmed Disability Improvement (CDI) in Open Label Extension (OLE) with up to 46 Months Follow up Patients Treated with ATA188 ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients ...
Atara Biotherapeutics shares fell Monday after the company said the U.S. health regulator didn't approve its therapy, backtracking on its previous guidance. Shares fell 53% to $6.40. The biotech ...
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results